Evidence map›Paper›PMID 40983806›Full record

ArticleEuropean journal of clinical pharmacology2025

Population pharmacokinetic characteristics of tacrolimus in Chinese lung transplant recipients and optimisation of dosing regimen during the early post-transplantation phase.

Shouning Zhou, Qiaoyan Lian, Huilong Luo, Hui Xie, Yanping Guan, Jianxing He, Li Wei, Chunrong Ju

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shouning Zhou *Department of Pharmacy, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Qiaoyan Lian *State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital, Guangzhou Medical University, Yanjiang Road, Guangzhou, 510120, China.
Huilong Luo *School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, China.
Hui XieDepartment of Pharmacy, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Yanping GuanInstitute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.
Jianxing HeState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital, Guangzhou Medical University, Yanjiang Road, Guangzhou, 510120, China.
Li WeiDepartment of Pharmacy, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Chunrong JuState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital, Guangzhou Medical University, Yanjiang Road, Guangzhou, 510120, China. juchunrongju@126.com.

Funding

the 2022 Pharmaceutical Research Fund of Guangdong Province Hospital Association 2022YXKY15the Foundation from Guangzhou Institute of Respiratory Health 2019 GIRHZ04the Foundation from The State Key Laboratory of Respiratory Disease SKLRD-QN-201710ZHONGNANSHAN Medical Foundation of Guangdong Province ZNSA-2020013
6 · The paper itself

Abstract

purposeThis study aimed to establish a population pharmacokinetic model and optimise tacrolimus dosing regimens in Chinese lung transplant recipients.

methodsA total of 988 tacrolimus trough concentrations and clinical data of 142 adult lung transplant recipients were collected. Population pharmacokinetic analysis was performed using a nonlinear mixed effects model. A Monte Carlo simulation was conducted to determine the optimal dosing regimen.

resultsThe pharmacokinetics of tacrolimus could be best described by a one-compartment model with first-order absorption and elimination. The typical population parameter estimates of apparent clearance and apparent volume of distribution were 7.58 L·h

conclusionRecipients with the CYP3A5*3/*3 genotype, elevated haematocrit levels, short postoperative days, and concurrent administration of azole antifungal drugs needed a reduced maintenance dose to reach the therapeutic window, which provided a reference for the formulation of individualised tacrolimus regimen during the early post-transplantation phase.

Indexed as

Immunosuppressive AgentsLung TransplantationModels, BiologicalTacrolimusAdultAgedChinaCytochrome P-450 CYP3AEast Asian PeopleFemaleHumansMaleMiddle AgedMonte Carlo MethodTransplant RecipientsYoung AdultCYP3A5 protein, humanCytochrome P-450 CYP3AImmunosuppressive AgentsTacrolimusLung transplantationMonte Carlo simulationNonlinear mixed effects modelPopulation pharmacokineticsTacrolimus

Identifiers

PMID40983806
PMCPMC12680674

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.